Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,245.90
(
0.51%
)
US TECH 100
26,975.60
(
1.00%
)
Dow Jones
49,584.38
(
-0.14%
)
Brent Oil
107.62
(
-2.48%
)
Bitcoin
78,232.31
(
2.49%
)
News Focus
News Focus
Post# of 257481
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122923
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: TwoNE1 post# 204502

Wednesday, 09/21/2016 4:38:17 PM

Wednesday, September 21, 2016 4:38:17 PM

Post# of 257481

OCRX—...no serious [drug-related] safety issues [in the phase-2a NIH trial].

Good news, but not surprising insofar as most of the patients in the phase-2a NIH trial used a smaller daily dose of OCR-002 than is being used in OCRX's own STOP-HE trial.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today